Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib
Rheumatology 2025;00:1–10 Doi: 10.1093/rheumatology/keaf547 Epub ahead of print
Hernández-Hernández et al. showed that in a real-world clinical settings, UPA persistence is lower among RA patients who have received prior IL-6i treatment; and that treatment strategies to avoid UPA in patients with cardiovascular risk (CVR) appear to be primarily driven by pivotal safety studies rather than regulatory guidance.